Floatz logo

Remimazolam

Desflurane

Seoul National University Bundang HospitalSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Desflurane cohort.

Asset / SponsorPhaseRating
Desflurane
Beijing Tiantan Hospital
Phase 2B
RAMIFENTANYL
Beijing Tiantan Hospital
N/AD
CISATRACURIUM ION
Beijing Tiantan Hospital
N/AD
SUFENTANIL CITRATE
Beijing Tiantan Hospital
N/AD
PROPOFOL
Beijing Tiantan Hospital
N/AD

Same molecule, other indications

Remimazolam is also rated in:

schizophreniaDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
69 / 100
View asset →
bipolar disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →